The Pyrimidin Analogue Cyclopentenyl Cytosine Induces Alloantigen-specific Non-responsiveness of Human T Lymphocytes

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2007 Dec 8

PMID 18062797

Authors

N Nikolaeva

F J Bemelman

S-L Yong

A Verschuur

R A W van Lier

I J M ten Berge

Affiliations

Soon will be listed here.

Abstract

Cyclopentenyl cytosine (CPEC) has been shown to induce apoptosis in human T lymphoblastic cell lines and T cells from leukaemia patients. In this study we have addressed the question of whether CPEC is able to decrease proliferation and effector functions of human alloresponsive T lymphocytes and induce T cell anergy. The proliferative capacity of human peripheral blood mononuclear cells in response to allogeneic stimulation was measured by 5,6-carboxy-succinimidyl-diacetate-fluorescein-ester staining. Flow cytometric analysis was performed using surface CD4, CD8, CD25, CD103 and intracellular perforin, granzyme A, granzyme B, caspase-3 and forkhead box P3 (FoxP3) markers. The in vivo immunosuppressive capacity was tested in a murine skin graft model. Addition of CPEC at a concentration of 20 nM strongly decreased the expansion and cytotoxicity of alloreactive T cells. Specific restimulation in the absence of CPEC showed that the cells became anergic. The drug induced caspase-dependent apoptosis of alloreactive T lymphocytes. Finally, CPEC increased the percentage of CD25(high) FoxP3+ CD4+ and CD103+ CD8+ T cells, and potentiated the effect of rapamycin in increasing the numbers of alloreactive regulatory T cells. Treatment with CPEC of CBA/CA mice transplanted with B10/Br skin grafts significantly prolonged graft survival. We conclude that CPEC inhibits proliferation and cytotoxicity of human alloreactive T cells and induces alloantigen non-responsiveness in vitro.

References

van den Berg A, van Lenthe H, Busch S, de Korte D, Roos D, van Kuilenburg A . Evidence for transformation-related increase in CTP synthetase activity in situ in human lymphoblastic leukemia. Eur J Biochem. 1993; 216(1):161-7. DOI: 10.1111/j.1432-1033.1993.tb18128.x. View

Kunz J, Henriquez R, Schneider U, Movva N, Hall M . Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993; 73(3):585-96. DOI: 10.1016/0092-8674(93)90144-f. View

Uss E, Yong S, Hooibrink B, van Lier R, Ten Berge I . Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro. Transplantation. 2007; 83(8):1098-106. DOI: 10.1097/01.tp.0000259555.29762.f0. View

Bierau J, van Gennip A, Helleman J, van Kuilenburg A . The cytostatic- and differentiation-inducing effects of cyclopentenyl cytosine on neuroblastoma cell lines. Biochem Pharmacol. 2001; 62(8):1099-105. DOI: 10.1016/s0006-2952(01)00756-0. View

Shigeta S, Konno K, Yokota T, Nakamura K, De Clercq E . Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro. Antimicrob Agents Chemother. 1988; 32(6):906-11. PMC: 172304. DOI: 10.1128/AAC.32.6.906. View

Agbaria R, Kelley J, Jackman J, Viola J, Ram Z, Oldfield E . Antiproliferative effects of cyclopentenyl cytosine (NSC 375575) in human glioblastoma cells. Oncol Res. 1997; 9(3):111-8. View

Chu C, Jin Y, Baker R, Huggins J . Antiviral activity of cyclopentenyl nucleosides against orthopox viruses (Smallpox, monkeypox and cowpox). Bioorg Med Chem Lett. 2002; 13(1):9-12. PMC: 9628949. DOI: 10.1016/s0960-894x(02)00841-7. View

Politi P, Xie F, Dahut W, Ford Jr H, Kelley J, Bastian A . Phase I clinical trial of continuous infusion cyclopentenyl cytosine. Cancer Chemother Pharmacol. 1995; 36(6):513-23. DOI: 10.1007/BF00685802. View

Yee L, Allegra C, Trepel J, Grem J . Metabolism and RNA incorporation of cyclopentenyl cytosine in human colorectal cancer cells. Biochem Pharmacol. 1992; 43(7):1587-99. DOI: 10.1016/0006-2952(92)90218-8. View

10.

Uss E, Rowshani A, Hooibrink B, Lardy N, van Lier R, Ten Berge I . CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J Immunol. 2006; 177(5):2775-83. DOI: 10.4049/jimmunol.177.5.2775. View

11.

Verschuur A, Brinkman J, van Gennip A, Leen R, Vet R, Evers L . Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line. Leuk Res. 2001; 25(10):891-900. DOI: 10.1016/s0145-2126(01)00047-9. View

12.

Medawar P . A second study of the behaviour and fate of skin homografts in rabbits; a report to the War Wounds Committee of the Medical Research Council. J Anat. 2010; 79:157-76. View

13.

Brown E, Albers M, Shin T, Ichikawa K, Keith C, Lane W . A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994; 369(6483):756-8. DOI: 10.1038/369756a0. View

14.

Ford Jr H, Cooney D, AHLUWALIA G, Hao Z, Rommel M, Hicks L . Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts. Cancer Res. 1991; 51(14):3733-40. View

15.

Huang J, Zhu H, Haggarty S, Spring D, Hwang H, Jin F . Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc Natl Acad Sci U S A. 2004; 101(47):16594-9. PMC: 527135. DOI: 10.1073/pnas.0407117101. View

16.

De Clercq E, Murase J, Marquez V . Broad-spectrum antiviral and cytocidal activity of cyclopentenylcytosine, a carbocyclic nucleoside targeted at CTP synthetase. Biochem Pharmacol. 1991; 41(12):1821-9. PMC: 7111160. DOI: 10.1016/0006-2952(91)90120-t. View

17.

Verschuur A, van Gennip A, Leen R, Muller E, Elzinga L, VOUTE P . Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia: a promising target for chemotherapy. Eur J Cancer. 2000; 36(5):627-35. DOI: 10.1016/s0959-8049(00)00021-6. View

18.

Lim M, Moyer J, Cysyk R, Marquez V . Cyclopentenyluridine and cyclopentenylcytidine analogues as inhibitors of uridine-cytidine kinase. J Med Chem. 1984; 27(12):1536-8. DOI: 10.1021/jm00378a002. View

19.

Parekh D, Ziegler W, Yonezawa K, Hara K, Parker P . Mammalian TOR controls one of two kinase pathways acting upon nPKCdelta and nPKCepsilon. J Biol Chem. 1999; 274(49):34758-64. DOI: 10.1074/jbc.274.49.34758. View

20.

Moyer J, Malinowski N, Treanor S, Marquez V . Antitumor activity and biochemical effects of cyclopentenyl cytosine in mice. Cancer Res. 1986; 46(7):3325-9. View